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Abstract: Clinical observations have revealed a strong correlation between loss of bone density 
in HIV-infected individuals, particularly in conjunction with the antiretroviral drug tenofovir, 
a nucleotide analog that inhibits HIV reverse transcriptase. The most compelling correlations 
have been observed in clinical studies involving young children and adolescents. These obser-
vations strongly suggest that bone density is being affected during active bone growth and 
development, implicating a role for tenofovir in bone loss. Here we discuss the literature and 
potential mechanisms for how tenofovir-associated bone loss may arise, which likely involves 
perturbation of cellular DNA synthesis and gene expression. Elucidation of the mechanism(s) 
involved in tenofovir-mediated bone loss will help in developing adjuvant therapies to reduce 
tenofovir-associated bone density loss.
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Introduction
Nucleoside reverse transcriptase inhibitors (NRTIs) represent the backbone of highly 
active antiretroviral therapy (HAART) for the clinical management of human immuno-
deficiency virus (HIV) infection. NRTIs target HIV reverse transcriptase and prevent 
the synthesis of viral DNA. NRTIs lack a 3′-hydroxyl group on the deoxyribose and 
following incorporation of the next incoming deoxynucleotide cannot form the new 
5′-3′ phosphodiester bond required to extend the synthesis of the DNA chain. Thus, 
NRTIs act as chain terminators of HIV DNA synthesis. Due to the development of HIV 
drug resistance, there has been a continual need for the discovery and development of 
new drug targets and new anti-HIV drugs.
Tenofovir, also called 9-(R)-{2-(phosphonomethoxy)propyl}adenine or PMPA, 
is a nucleotide analog (Figure 1) and was approved in 2001 for use in treating HIV 
infection and more recently for chronic hepatitis B infection.1 The prodrug form is 
tenofovir disoproxil fumarate (TDF) (Figure 1). Tenofovir has improved potency as 
it is a nucleotide and has an abbreviated intracellular activation pathway to allow a 
more rapid and complete conversion to the active drug. The prodrug TDF has a labile 
lipophilic group to facilitate penetration through target cell membranes. Tenofovir 
is not known to be a substrate, inducer or inhibitor of human cytochrome P450 
enzymes in vitro or in vivo. Tenofovir has high potency and an unusually durable 
response when used in trials of single-agent therapy intensification in highly treatment-
experienced individuals.2 The active metabolite, tenofovir diphosphate, exhibits a 
long intracellular half-life in both resting and activated peripheral blood mononuclear 
cells, which allows for single daily dosing. The clinical efficacy of TDF has been Therapeutics and Clinical Risk Management 2010:6 42
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shown in Phase II (ie, GS-98-902) and III (ie, GS-99-907) 
clinical trials, with highly treatment-experienced patients.3,4 
The Phase II and III studies were both randomized, double-
blind, placebo-controlled, multicenter intensification studies 
of TDF that confirmed the utility of TDF in which patients 
added TDF therapy (300 mg once daily) in addition to their 
existing regimen.5
While there has been great success in the use of tenofovir 
in treating HIV infection, there have been clinical reports of 
tenofovir-associated side effects. Among those side effects, 
multiple studies have implicated tenofovir-associated bone 
loss. This review discusses the literature on tenofovir-
associated bone loss and presents several plausible mecha-
nisms that might explain the basis for bone loss.
Tenofovir-associated bone loss
Bone is a dynamic tissue that is formed and maintained by 
osteoblasts (which form bone) and osteoclasts (which resorb 
bone). An extensive cell signaling network between osteo-
blasts and osteoclasts is required for maintaining a balance 
in the activities of these two cell types in bone remodeling 
and bone health. Recent studies have indicated that direct 
signals between bone cells are important for regulating 
bone remodeling.6–8 For example, it has been shown that 
osteoclasts can initiate bone formation via signaling to 
osteoblasts independent of their ability to resorb bone.9,10 
In patients with autosomal dominant osteopetrosis type II it 
was demonstrated that the number of osteoclasts but not their 
activity controls bone formation.11 Conversely, osteoblasts 
regulate osteoclast differentiation by expressing two factors 
that are necessary and sufficient for osteoclast formation: 
M-CSF12 and RANKL13; M-CSF is required for survival and 
proliferation of early osteoclast precursors.14–16 Binding of 
RANKL, produced by osteoblasts, and the RANK receptor 
on osteoclasts stimulates expression of genes necessary for 
osteoclast differentiation, cellular fusion and bone resorption. 
Additionally, osteoblasts express osteoprotegerin, a soluble 
decoy receptor for RANKL, which inhibits activation of 
RANK by RANKL. The ratio of RANKL to osteoprotegerin 
produced by osteoblasts is a major determinant of osteoclast 
forming activity within the bone microenvironment and 
allows for close coordination between bone formation and 
bone resorption under normal physiological conditions.
Perturbations in the function of osteoblasts or osteoclasts 
can lead to bone loss, clinically presented as osteopenia or 
osteoporosis. Osteoporosis commonly occurs in women 
following menopause, where it is called postmenopausal 
osteoporosis, but can also occur in men or anyone with certain 
hormonal disorders, other chronic diseases, or due to medica-
tions such as glucocorticoids.17–23 Vitamin D deficiencies can 
result in bone softening, resulting in osteomalacia – in children 
called rickets.24–26 Loss of osteoclast function increases bone 
density, resulting in osteopetrosis. One example of a human 
condition involving osteopetrosis is a rare inherited disorder, 
called Albers–Schonberg disease. In osteopetrosis, osteoclast 
numbers may be lower, normal, or elevated, however the critical 
factor in the development of osteopetrosis is the dysfunction 
of osteoclasts. For example, a reduction of carbonic anhydrase 
expression in osteoclasts can result in defects in hydrogen ion 
pumping, which can cause a dysfunction in osteoclast resorp-
tion of bone.27,28 However, osteoblast dysfunction, particularly 
hyperactivity, can also result in osteopetrosis29,30 while a 
decrease in function can contribute to osteoporosis.
HIV infection has been implicated as a risk factor for 
alteration of bone mineral density in children as well as 
in adults.31–34 Imbalances in growth factors and cytokines, 
as well as the use of HAART could contribute to bone 
loss by increasing bone resorption. Previous studies have 
demonstrated adverse effects on bone metabolism by the 
administration of tenofovir in macaques, resulting primarily 
in decreased bone density.35–37 Infection of macaques by 
simian immunodeficiency virus was also implicated in 
affecting bone density. Histomorphometric analysis revealed 
in one of these studies an increase in tibial osteoid seam 
width, which can result in bone softening (and can develop 
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into osteomalacia).35 The increase in osteoid seam width is 
likely associated with reduced activity in osteoblasts. Bone 
density reductions due to tenofovir have also been reported 
in human adults.38 Since tenofovir has a distinct and unique 
drug resistance profile, it satisfies the significant need for 
new non-cross-resistant HAART regimens in salvage therapy, 
particularly with children and adolescents. In light of this, off-
label clinical studies of tenofovir with HIV-infected children 
and adolescents have been conducted to investigate the 
efficacy of tenofovir-containing HAART regimens and to 
investigate whether tenofovir-associated bone loss is greater 
in children and adolescents than in adults.39–41 Increased 
bone resorption could cause a compensatory increase in 
osteoblast activity, which would be revealed by increased 
serum alkaline phosphatase levels.42 General conclusions 
drawn from these studies include that tenofovir treatment 
decreased bone mineral density as well as increased urinary 
calcium excretion. One limitation of these studies was the 
relatively small study size (ranging from 18 to 6 children). 
Another limitation of these studies is that the measurement of 
bone density is difficult in children and adolescents because 
of the dynamic yet variable rate of bone growth. Presently, 
there are different methods that are commonly used to mea-
sure bone density: dual-energy X-ray absorbtiometry (DXA), 
quantitative computed tomography (QCT), and quantitative 
ultrasound (QUS). Each approach has limitations and compar-
isons between these methods are difficult as comparative data 
analysis can be somewhat subjective. A study that analyzed 
the effect of TDF treatment of a group of 16 HIV-infected 
children and adolescents over a 1-year period concluded that 
TDF did not affect bone density when stavudine and protease 
inhibitor-containing regimens were compared with TDF/lami-
vudine/efavirenz.43 Differences in this study compared to that 
of the previously described studies include that the patients 
were older, had greater height and weight, and the majority 
were either in middle or late puberty or postpubertal. The 
children under study were also required to have long-lasting 
viral suppression prior to the switch to TDF and were exposed 
to TDF levels that may have been lower, as fractions of pills 
were administered. This study design is different to the other 
studies, which involved relatively younger children that did 
not have long lasting viral suppression prior to the switch to 
TDF, which were entire pills (ie, 300 mg).39–41
Mechanisms of tenofovir-associated 
bone loss
A significant literature exists on NRTIs that have implicated 
mitochondrial dysfunction, reviewed in.44–49 The inhibition of 
mitochondrial polymerase gamma could occur by competitive 
inhibition of polymerase gamma and/or the incorporation 
and subsequent DNA chain termination. The result would be 
a reduction in mitochondrial DNA synthesis. NRTIs could 
also indirectly inhibit DNA synthesis by inducing nucleo-
tide pool imbalances, oxidative stress, and DNA damage. 
Both direct and indirect mechanisms would result in the 
alteration of mitochondrial gene expression, which would 
cause mitochondrial dysfunction. NRTIs have greater affinity 
for affecting different tissue types as well as the nature of 
the mitochondrial-induced dysfunction in these tissue types, 
depending upon the NRTI. The analysis of NRTI-associated 
cellular stress has indicated that the mechanisms involved can 
be quite complex. NRTIs can result in altered gene expres-
sion profiles.50,51 Altered gene expression profiles have been 
observed in the absence of mitochondrial DNA depletion, 
suggesting that NRTIs can cause mitochondrial dysfunction 
and not inhibit mitochondrial DNA polymerase gamma.52
The association of tenofovir with mitochondrial dys-
function has been investigated. In general, no mitochondrial 
dysfunction was observed with tenofovir.53–56 Other studies 
have reported a lowering of mitochondrial dysfunction when 
drug regimens were changed and NRTIs were replaced with 
tenofovir.57–59 A recent study in rats found that very high doses 
(ie, 100 mg/kg/day) of tenofovir reduced mitochondrial DNA 
and gene expression in kidney cells.60 The relevance of this 
observation given the very high dosing used is unclear. In 
stark contrast, in an HIV transgenic mouse model tenofovir 
treatment was found to increase mitochondrial DNA content 
in kidney cells.61 Further analysis of mitochondrial DNA 
obtained from renal proximal tubules microdissected from 
kidney sections suggested that tenofovir lowered mitochon-
drial DNA levels in the renal proximal tubules.61 To date, no 
studies of mitochondrial dysfunction being associated with 
tenofovir-mediated bone loss have been reported. Overall, the 
current literature does not provide strong evidence for mito-
chondrial dysfunction being a major mechanism for tenfovir-
mediated cellular stress, particularly in regards to bone loss.
In vitro studies have previously reported that tenofovir 
diphosphate is a poor substrate and weak inhibitor of rat DNA 
polymerase alpha, delta and epsilon.55 Combined with the 
report of tenofovir diphosphate being poorly incorporated 
into DNA by the human mitochondrial DNA polymerase 
gamma,49 data are limited that would support a direct role 
of tenofovir in bone loss by the inhibition of either nuclear 
or mitochondrial DNA replication. While data are lack-
ing for tenofovir diphosphate being a good substrate for 
cellular DNA polymerases, the in vivo data correlating Therapeutics and Clinical Risk Management 2010:6 44
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tenofovir therapy with bone loss, particularly in children 
and adolescents who have very active and ongoing bone 
growth, implicate a role for tenofovir’s ability to impact 
cellular DNA synthesis. Such an impact could be either 
direct or indirect, such as 1) incorporation and DNA chain 
termination, 2) DNA damage, 3) alteration of deoxynucleo-
tide transport, and/or 4) nucleotide pool imbalances, which 
would perturb cellular DNA synthesis. The perturbation of 
cellular (ie, nuclear and/or mitochondrial) DNA synthesis 
would result in altered gene expression. The alteration of 
gene expression for genes involved in bone maintenance 
could explain the clinical observation of bone density loss 
during tenofovir treatment.
We propose three potential mechanisms for tenofovir-
associated bone loss. These include 1) preferential uptake by 
osteoclasts (altering gene expression and resulting in increased 
bone resorption), 2) update by osteoblasts (altering gene expres-
sion and decreasing bone formation), and 3) uptake by both 
osteoclasts and osteoblasts (altering gene expression of both 
cells types and ultimately the balance between bone resorp-
tion and bone formation – resulting in bone loss).
Since TDF is a phosphonate, it is possible that this could 
enhance its uptake into cells (Figure 2A), which would 
increase the probability of cellular stress. Bisphosphonates 
(ie, diphosphonates) are drugs used clinically to prevent loss 
of bone density, particularly in diseases such as osteoporosis, 
bone metastasis, multiple myeloma, Paget’s disease of bone, 
and primary hyperparathyroidism. Bisphosphonates target 
bone and inhibit osteoclast function after their cellular uptake 
by inducing apoptosis.62,63 Since tenofovir and TDF are both 
phosphonates, it is conceivable that they could also have an 
association with bone and be selectively taken up by osteo-
clasts by a mechanism similar to that of bisphosphonates, 
ultimately causing cellular stress. The resulting cellular stress 
would likely perturb cellular DNA synthesis (ie, nuclear 
and/or mitochondrial) and gene expression (Figure 2B). 
For example, the reduction of gene expression for an 
osteoclast gene that is involved in signaling osteoblast activity 
could ultimately result in a loss of bone density. It is formally 
possible that adjuvant treatment of bone density loss could 
improve the durability of tenofovir-containing HAART. 
In the case of osteoclast hyperactivity, it is possible that 
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Figure 2  The osteoclast as a target for   TDF.  A) Bone tissue, osteoblasts and osteoclasts. TDF, as a phosphonate, associates with bone tissue. Bone resorption by osteoclasts 
would result in the preferential uptake of   TDF.  B) Impact of  TDF on osteoclast DnA synthesis and gene expression. Following   TDF uptake by osteoclasts,   TDF can target the 
nucleus (1) and/or mitochondria (2), where it may directly or indirectly perturb DnA synthesis by 1) incorporation and DnA chain termination, 2) DnA damage, 3) alteration 
of deoxynucleotide transport, and/or 4) nucleotide pool imbalances.   The impact of  TDF on cellular DnA synthesis would result in altered gene expression (3).
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bisphosphonates could reduce bone density loss associated 
with tenofovir treatment.
The loss of bone density due to TDF exposure could also 
be associated with tenofovir-induced renal dysfunction – 
particularly renal proximal tubule dysfunction.42,61,64–72 The 
failure of renal proximal tubular cells to reabsorb filtered 
bicarbonate from the urine would result in urinary bicar-
bonate wasting and subsequent acidemia and a more 
general dysfunction of the proximal tubular cells – called 
Fanconi’s syndrome. Commonly observed conditions in 
Fanconi syndrome include aminoaciduria, glycosuria, tubular 
proteinuria, and uricosuria. Importantly, the main clinical 
feature of Fanconi’s syndrome is bone demineralization 
(osteomalacia or rickets) due to phosphate wasting. There-
fore, TDF-associated bone density loss may an outcome of 
renal dysfunction.
Summary
The distinctive resistance profile, high potency and limited 
side effects of tenofovir have made it an important component 
of HAART. The off-label use of tenofovir for treatment of 
children and adolescents is important for providing alterna-
tives to treatment-experienced patients. Also, tenofovir will 
likely play an important role in preventing mother-to-child 
transmission, particularly in the context of the appeal of 
TDF-containing fixed dose combinations in a single pill 
(ie, Atripla® and Truvada®). A concern in off-label tenofovir 
use is bone density loss. Current data indicate that tenofovir-
mediated bone loss is likely mediated by novel mechanisms 
not solely related to the known mitochondrial dysfunction 
associated with NRTIs. Future research will further aid in the 
elucidation the mechanism(s) involved in tenofovir-mediated 
bone loss, which would help in developing adjuvant therapies 
to reduce tenofovir-associated bone density loss.
Acknowledgments
We thank Steve Patterson for stimulating discussions. 
Supported by NIH grants AR53946 (K.C.M.), DE16093 
(R.G.), and GM56615 (L.M.M.). I.F.G. and L.P. were 
supported by the MinnCResT Program, T32DE07288.
Disclosures
The authors declare no conflicts of interest.
References
  1.  Pozniak A. Tenofovir: what have over 1 million years of patient 
experience taught us? Int J Clin Pract. 2008;62(8):1285–1293.
  2.  Stephan C. Experience with tenofovir disoproxil fumarate for antiretroviral 
therapy. Expert Opin Pharmacother. 2008;9(7):1197–1209.
  3.  Margot NA, Isaacson E, McGowan I, Cheng AK, Schooley RT, 
Miller MD. Genotypic and phenotypic analyses of HIV-1 in antiretroviral-
experienced patients treated with tenofovir DF. AIDS. 2002;16(9): 
1227–1235.
  4.  Schooley RT, Ruane P, Myers RA, et al. Tenofovir DF in antiretroviral-
experienced patients: results from a 48-week, randomized, double-
blind study. AIDS. 2002;16(9):1257–1263.
  5.  Squires K, Pozniak AL, Pierone G Jr, et al. Tenofovir disoproxil fumarate 
in nucleoside-resistant HIV-1 infection: a randomized trial. Ann Intern 
Med. 2003;139(5 Pt 1):313–320.
  6.  Karsdal MA, Martin TJ, Bollerslev J, Christiansen C, Henriksen K. 
Are nonresorbing osteoclasts sources of bone anabolic activity? J Bone 
Miner Res. 2007;22(4):487–494.
  7.  Karsdal MA, Henriksen K, Sorensen MG, et al. Acidification of the 
osteoclastic resorption compartment provides insight into the coupling of 
bone formation to bone resorption. Am J Pathol. 2005;166(2):467–476.
  8.  Martin TJ, Sims NA. Osteoclast-derived activity in the coupling of bone 
formation to resorption. Trends Mol Med. 2005;11(2):76–81.
  9.  Bollerslev J, Marks SC Jr, Pockwinse S, et al. Ultrastructural investi-
gations of bone resorptive cells in two types of autosomal dominant 
osteopetrosis. Bone. 1993;14(6):865–869.
10.  Bollerslev J, Steiniche T, Melsen F, Mosekilde L. Structural and his-
tomorphometric studies of iliac crest trabecular and cortical bone in 
autosomal dominant osteopetrosis: a study of two radiological types. 
Bone. 1989;10(1):19–24.
11.  Alatalo SL, Ivaska KK, Waguespack SG, Econs MJ, Vaananen HK, 
Halleen JM. Osteoclast-derived serum tartrate-resistant acid phos-
phatase 5b in Albers-Schonberg disease (type II autosomal dominant 
osteopetrosis). Clin Chem. 2004;50(5):883–890.
12.  Cecchini MG, Hofstetter W, Halasy J, Wetterwald A, Felix R. Role 
of CSF-1 in bone and bone marrow development. Mol Reprod Dev. 
1997;46(1):75–83; discussion 83–74.
13.  Wada T, Nakashima T, Hiroshi N, Penninger JM. RANKL-RANK 
signaling in osteoclastogenesis and bone disease. Trends Mol Med. 
2006;12(1):17–25.
14.  Felix R, Cecchini MG, Hofstetter W, Elford PR, Stutzer A, Fleisch H. 
Impairment of macrophage colony-stimulating factor production and 
lack of resident bone marrow macrophages in the osteopetrotic op/op 
mouse. J Bone Miner Res. 1990;5(7):781–789.
15.  Wiktor-Jedrzejczak W, Bartocci A, Ferrante AW Jr, et al. Total absence 
of colony-stimulating factor 1 in the macrophage-deficient osteopetrotic 
(op/op) mouse. Proc Natl Acad Sci U S A. 1990;87(12):4828–4832.
16.  Yoshida H, Hayashi S, Kunisada T, et al. The murine mutation osteo-
petrosis is in the coding region of the macrophage colony stimulating 
factor gene. Nature. 1990;345(6274):442–444.
17.  Bonnelye E, Merdad L, Kung V , Aubin JE. The orphan nuclear estrogen 
receptor-related receptor alpha (ERRalpha) is expressed throughout 
osteoblast differentiation and regulates bone formation in vitro. J Cell 
Biol. 2001;153(5):971–984.
18.  Liu RH, Werth VP. What is new in the treatment of steroid-induced 
osteoporosis? Semin Cutan Med Surg. 2007;26(4):203–209.
19.  Shaker JL, Lukert BP. Osteoporosis associated with excess glucocorticoids. 
Endocrinol Metab Clin North Am. 2005;34(2):341–356, viii–ix.
20.  Caplan L, Saag KG. Glucocorticoids and the risk of osteoporosis. Expert 
Opin Drug Saf. 2009;8(1):33–47.
21. Ebeling PR. Osteoporosis in men. New insights into aetiology, pathogen-
esis, prevention and management. Drugs Aging. 1998;13(6):421–434.
22.  McIlwain HH. Glucocorticoid-induced osteoporosis: pathogenesis, 
diagnosis, and management. Prev Med. 2003;36(2):243–249.
23.  Pietschmann P, Rauner M, Sipos W, Kerschan-Schindl K. Osteoporosis: 
an age-related and gender-specific disease – a mini-review. Gerontology. 
2008;55(1):3–12.
24.  Frame B, Parfitt AM. Osteomalacia: current concepts. Ann Intern Med. 
1978;89(6):966–982.
25.  Misra M, Pacaud D, Petryk A, Collett-Solberg PF, Kappy M. Vitamin D 
deficiency in children and its management: review of current knowledge 
and recommendations. Pediatrics. 2008;122(2):398–417.Therapeutics and Clinical Risk Management 2010:6 46
Grigsby et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
26.  Ukinc K. Severe osteomalacia presenting with multiple vertebral 
fractures: a case report and review of the literature. Endocrine. 
2009;36(1):30–36.
27.  Segovia-Silvestre T, Neutzsky-Wulff AV , Sorensen MG, et al. Advances 
in osteoclast biology resulting from the study of osteopetrotic mutations. 
Hum Genet. 2009;124(6):561–577.
28.  Sly WS, Hewett-Emmett D, Whyte MP, Yu YS, Tashian RE. Carbonic 
anhydrase II deficiency identified as the primary defect in the autoso-
mal recessive syndrome of osteopetrosis with renal tubular acidosis 
and cerebral calcification. Proc Natl Acad Sci U S A. 1983;80(9): 
2752–2756.
29.  Boyden LM, Mao J, Belsky J, et al. High bone density due to a muta-
tion in LDL-receptor-related protein 5. N Engl J Med. 2002;346(20): 
1513–1521.
30.  Van Wesenbeeck L, Cleiren E, Gram J, et al. Six novel missense 
mutations in the LDL receptor-related protein 5 (LRP5) gene in dif-
ferent conditions with an increased bone density. Am J Hum Genet. 
2003;72(3):763–771.
31.  Arpadi SM, Horlick M, Thornton J, Cuff PA, Wang J, Kotler DP. Bone 
mineral content is lower in prepubertal HIV-infected children. J Acquir 
Immune Defic Syndr. 2002;29(5):450–454.
32.  Tebas P, Powderly WG, Claxton S, et al. Accelerated bone mineral loss 
in HIV-infected patients receiving potent antiretroviral therapy. AIDS. 
2000;14(4):F63–F67.
33.  Vigano A, Mora S. Adverse effects of antiretroviral therapy: focus on 
bone density. Expert Opin Drug Saf. 2004;3(3):199–208.
34.  Madeddu G, Spanu A, Solinas P, et al. Bone mass loss and vitamin 
D metabolism impairment in HIV patients receiving highly active 
antiretroviral therapy. Q J Nucl Med Mol Imaging. 2004;48(1): 
39–48.
35.  Castillo AB, Tarantal AF, Watnik MR, Martin RB. Tenofovir treatment 
at 30 mg/kg/day can inhibit cortical bone mineralization in grow-
ing rhesus monkeys (Macaca mulatta). J Orthop Res. 2002;20(6): 
1185–1189.
36.  Tarantal AF, Marthas ML, Shaw JP, Cundy K, Bischofberger N. 
Administration of 9-[2-(R)-(phosphonomethoxy)propyl]adenine 
(PMPA) to gravid and infant rhesus macaques (Macaca mulatta): safety 
and efficacy studies. J Acquir Immune Defic Syndr Hum Retrovirol. 
1999;20(4):323–333.
37.  Van Rompay KK, Brignolo LL, Meyer DJ, et al. Biological effects of 
short-term or prolonged administration of 9-[2-(phosphonomethoxy) 
propyl]adenine (tenofovir) to newborn and infant rhesus macaques. 
Antimicrob Agents Chemother. 2004;48(5):1469–1487.
38.  Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of 
tenofovir DF vs stavudine in combination therapy in antiretroviral-naive 
patients: a 3-year randomized trial. JAMA. 2004;292(2):191–201.
39.  Hazra R, Gafni RI, Maldarelli F, et al. Tenofovir disoproxil fumarate 
and an optimized background regimen of antiretroviral agents as 
salvage therapy for pediatric HIV infection. Pediatrics. 2005;116(6):
e846–e854.
40.  Gafni RI, Hazra R, Reynolds JC, et al. Tenofovir disoproxil fumarate 
and an optimized background regimen of antiretroviral agents as sal-
vage therapy: impact on bone mineral density in HIV-infected children. 
Pediatrics. 2006;118(3):e711–e718.
41.  Purdy JB, Gafni RI, Reynolds JC, Zeichner S, Hazra R. Decreased 
bone mineral density with off-label use of tenofovir in children and 
adolescents infected with human immunodeficiency virus. J Pediatr. 
2008;152(4):582–584.
42.  Fux CA, Rauch A, Simcock M, et al. Tenofovir use is associated with 
an increase in serum alkaline phosphatase in the Swiss HIV Cohort 
Study. Antivir Ther. 2008;13(8):1077–1082.
43.  Giacomet V , Mora S, Martelli L, Merlo M, Sciannamblo M, Vigano A. 
A 12-month treatment with tenofovir does not impair bone mineral 
accrual in HIV-infected children. J Acquir Immune Defic Syndr. 2005; 
40(4):448–450.
44.  Cote HC. Mechanisms of antiretroviral therapy-induced mitochondrial 
dysfunction. Curr Opin HIV AIDS. 2007;2(4):253–260.
45.  Lewis W, Copeland WC, Day BJ. Mitochondrial dna depletion, oxidative 
stress, and mutation: mechanisms of dysfunction from nucleoside 
reverse transcriptase inhibitors. Lab Invest. 2001;81(6):777–790.
46.  Lewis W, Day BJ, Copeland WC. Mitochondrial toxicity of NRTI 
antiviral drugs: an integrated cellular perspective. Nat Rev Drug Discov. 
2003;2(10):812–822.
47.  Lewis W, Kohler JJ, Hosseini SH, et al. Antiretroviral nucleosides, 
deoxynucleotide carrier and mitochondrial DNA: evidence supporting 
the DNA pol gamma hypothesis. AIDS. 2006;20(5):675–684.
48.  Kohler JJ, Lewis W. A brief overview of mechanisms of mitochondrial 
toxicity from NRTIs. Environ Mol Mutagen. 2007;48(3–4):166–172.
49.  Lee H, Hanes J, Johnson KA. Toxicity of nucleoside analogues used to 
treat AIDS and the selectivity of the mitochondrial DNA polymerase. 
Biochemistry. 2003;42(50):14711–14719.
50.  Desai VG, Lee T, Delongchamp RR, et al. Nucleoside reverse transcrip-
tase inhibitors (NRTIs)-induced expression profile of mitochondria-
related genes in the mouse liver. Mitochondrion. 2008;8(2):181–195.
51.  Desai VG, Lee T, Moland CL, et al. Effect of short-term exposure to 
zidovudine (AZT) on the expression of mitochondria-related genes 
in skeletal muscle of neonatal mice. Mitochondrion. 2009;9(1): 
9–16.
52.  Mallon PW, Unemori P, Sedwell R, et al. In vivo, nucleoside reverse-
transcriptase inhibitors alter expression of both mitochondrial and lipid 
metabolism genes in the absence of depletion of mitochondrial DNA. 
J Infect Dis. 2005;191(10):1686–1696.
53.  Vidal F, Domingo JC, Guallar J, et al. In vitro cytotoxicity and mito-
chondrial toxicity of tenofovir alone and in combination with other 
antiretrovirals in human renal proximal tubule cells. Antimicrob Agents 
Chemother. 2006;50(11):3824–3832.
54.  Cihlar T, Birkus G, Greenwalt DE, Hitchcock MJ. Tenofovir exhibits 
low cytotoxicity in various human cell types: comparison with other 
nucleoside reverse transcriptase inhibitors. Antiviral Res. 2002;54(1): 
37–45.
55.  Birkus G, Hitchcock MJ, Cihlar T. Assessment of mitochondrial toxicity 
in human cells treated with tenofovir: comparison with other nucleo-
side reverse transcriptase inhibitors. Antimicrob Agents Chemother. 
2002;46(3):716–723.
56.  Biesecker G, Karimi S, Desjardins J, et al. Evaluation of mitochondrial 
DNA content and enzyme levels in tenofovir DF-treated rats, rhesus 
monkeys and woodchucks. Antiviral Res. 2003;58(3):217–225.
57.  Gerschenson M, Kim C, Berzins B, et al. Mitochondrial function, 
morphology and metabolic parameters improve after switching from 
stavudine to a tenofovir-containing regimen. J Antimicrob Chemother. 
2009;63(6):1244–1250.
58.  Ribera E, Paradineiro JC, Curran A, et al. Improvements in subcutaneous 
fat, lipid profile, and parameters of mitochondrial toxicity in patients 
with peripheral lipoatrophy when stavudine is switched to tenofovir 
(LIPOTEST study). HIV Clin Trials. 2008;9(6):407–417.
59.  Miro O, Garrabou G, Lopez S, et al. Short communication metabolic 
and mitochondrial effects of switching antiretroviral-experienced 
patients to enfuvirtide, tenofovir and saquinavir/ritonavir. Antivir Ther. 
2006;11(5):625–630.
60.  Lebrecht D, Venhoff AC, Kirschner J, Wiech T, Venhoff N, Walker 
UA. Mitochondrial tubulopathy in tenofovir disoproxil fumarate-treated 
rats. J Acquir Immune Defic Syndr. 2009;51(3):258–263.
61.  Kohler JJ, Hosseini SH, Hoying-Brandt A, et al. Tenofovir renal 
toxicity targets mitochondria of renal proximal tubules. Lab Invest. 
2009;89(5):513–519.
62.  Kwak HB, Kim JY, Kim KJ, et al. Risedronate directly inhibits osteo-
clast differentiation and inflammatory bone loss. Biol Pharm Bull. 
2009;32(7):1193–1198.
63.  Moreau MF, Guillet C, Massin P, et al. Comparative effects of five 
bisphosphonates on apoptosis of macrophage cells in vitro. Biochem 
Pharmacol. 2007;73(5):718–723.
64.  Earle KE, Seneviratne T, Shaker J, Shoback D. Fanconi’s syndrome in 
HIV+ adults: report of three cases and literature review. J Bone Miner 
Res. 2004;19(5):714–721.Therapeutics and Clinical Risk Management 2010:6
Therapeutics and Clinical Risk Management
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/therapeutics-and-clinical-risk-management-journal
Therapeutics and Clinical Risk Management is an international, peer-
reviewed journal of clinical therapeutics and risk management, focusing 
on concise rapid reporting of clinical studies in all therapeutic areas, 
outcomes, safety, and programs for the effective, safe, and sustained 
use of medicines. This journal is indexed on PubMed Central, CAS, 
EMBase, Scopus and the Elsevier Bibliographic databases. The 
manuscript management system is completely online and includes a 
very quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.
47
Tenofovir and bone loss Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
65.  Parsonage MJ, Wilkins EG, Snowden N, Issa BG, Savage MW. The 
development of hypophosphataemic osteomalacia with myopathy in 
two patients with HIV infection receiving tenofovir therapy. HIV Med. 
2005;6(5):341–346.
66.  Williams J, Chadwick DR. Tenofovir-induced renal tubular dysfunction 
presenting with hypocalcaemia. J Infect. 2006;52(4):e107–e108.
67.  Nelson MR, Katlama C, Montaner JS, et al. The safety of tenofovir 
disoproxil fumarate for the treatment of HIV infection in adults: the 
first 4 years. AIDS. 2007;21(10):1273–1281.
68.  Labarga P, Barreiro P, Martin-Carbonero L, et al. Kidney tubular 
abnormalities in the absence of impaired glomerular function in HIV 
patients treated with tenofovir. AIDS. 2009;23(6):689–696.
69.  Woodward CL, Hall AM, Williams IG, et al. Tenofovir-associated renal 
and bone toxicity. HIV Med. 2009;10(8):482–487.
70.  Perrot S, Aslangul E, Szwebel T, Caillat-Vigneron N, Le Jeunne C. Bone 
pain due to fractures revealing osteomalacia related to tenofovir-induced 
proximal renal tubular dysfunction in a human immunodeficiency virus-
infected patient. J Clin Rheumatol. 2009;15(2):72–74.
71.  Calmy A, Fux CA, Norris R, et al. Low bone mineral density, renal 
dysfunction, and fracture risk in HIV infection: a cross-sectional study. 
J Infect Dis. 2009;200(11):1746–1754.
72.  Di Biagio A, Rosso R, Monteforte P, Russo R, Rovetta G, Viscoli C. 
Whole body bone scintigraphy in tenofovir-related osteomalacia: a case 
report. J Med Case Reports. 2009;3:8136.